Literature DB >> 20954445

Development of a multiplex PCR for the simultaneous amplification and genotyping of glycoprotein N among human cytomegalovirus strains.

Sara Pignatelli1, Daniela Maurizio, Maria Paola Ladini, Paola Dal Monte.   

Abstract

Genomic variation among human cytomegalovirus (HCMV) strains is probably involved in HCMV-induced pathogenesis. The envelope glycoprotein N (gN) showed extensive genetic polymorphism as HCMV isolates have been clustered into four distinct gN variants (gN-1, gN-2, gN-3, gN-4) whose distribution has been analyzed worldwide using different methodological approaches (PCR-RFLP, PCR-Cloning, PCR-Sequencing). This paper describes a new method for concurrent detection of gN genotypes among HCMV strains using a multiplex gN-variants specific PCR plus visualization on agarose gel, avoiding subsequent steps such as cloning, restriction or sequencing. This novel approach will reduce costs and shorten the detection time of gN polymorphisms among HCMV clinical isolates.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20954445

Source DB:  PubMed          Journal:  New Microbiol        ISSN: 1121-7138            Impact factor:   2.479


  3 in total

1.  Diagnostic consequences of cytomegalovirus glycoprotein B polymorphisms.

Authors:  Zdenek Novak; Nazma Chowdhury; Shannon A Ross; Sunil K Pati; Karen Fowler; Suresh B Boppana
Journal:  J Clin Microbiol       Date:  2011-06-08       Impact factor: 5.948

2.  Human cytomegalovirus glycoprotein polymorphisms and increasing viral load in AIDS patients.

Authors:  Xiao-Jing Jiang; Jun Zhang; Yong Xiong; Gerhard Jahn; Hai-Rong Xiong; Zhan-Qiu Yang; Yuan-Yuan Liu
Journal:  PLoS One       Date:  2017-05-03       Impact factor: 3.240

3.  Inflammatory breast cancer: high incidence of detection of mixed human cytomegalovirus genotypes associated with disease pathogenesis.

Authors:  Hossam Taha Mohamed; Mohamed El-Shinawi; M Akram Nouh; Abdel-Rahman Bashtar; Elsayed Tarek Elsayed; Robert J Schneider; Mona Mostafa Mohamed
Journal:  Front Oncol       Date:  2014-09-11       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.